Xenon Pharmaceuticals Inc (XENE) - Market Cap to Earnings

Xenon Corp - graphic logo of issuer XENE

Xenon Pharmaceuticals (XENE) is currently in the final stages of clinical trials, meaning a lack of sales combined with rising R&D costs is keeping operating leverage in negative territory. The P/E ratio trend on the GURU.Markets chart, where the metric settled at -9.20, confirms this current stage. The company is developing unique channel modulators to combat epilepsy while outsourcing production and logistics to third-party contractors.

Xenon Pharmaceuticals Inc - XENE Price to Earnings Ratio (period 07/04/2022 - 11/16/2026)

Analytical breakdowns for Xenon Pharmaceuticals (XENE)

- current price and projected stock value:
Comprehensive company analysis:Xenon (XENE)
Product sample of Xenon Corp

The P/E ratio reflects the market value of a business relative to its net income, allowing for an assessment of the investment payback period through the lens of current yield. By analyzing the target P/E of the company, an investor compares market expectations with the fundamental value of Xenon Pharmaceuticals (XENE), where a high valuation is justified by an academic approach to developing epilepsy drugs and success in progressing through clinical phases.

Key competitors

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|Viking Therapeutics Inc - P/E Multiple|Market Cap to Earnings Supernus Pharmaceuticals, Inc.|Catalyst Pharmaceuticals Inc (CPRX) - Price to Earnings Ratio|DNLI (Denali Therapeutics Inc) - Price to Earnings Ratio|Price to Earnings Ratio Harmony Biosciences Holdings, Inc.|Price to Earnings Ratio BHVN|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals, Inc.)|Market Price to Net Income Ratio TRVI|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple